Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease.

ABSTRACT:

Introduction

Overt fibrostenotic disease is a relative contraindication for anti-TNF therapy in Crohn's disease. We hypothesized that subclinical fibrosis may also contribute to an incomplete response to anti-TNF therapy before the onset of symptomatic stenosis.

Methods

In a previous trial, patients with ileocecal Crohn's disease were randomized to either immediate ileocecal resection or medical treatment with Infliximab. In case of insufficient response to Infliximab, the latter underwent secondary ileocecal resection. We compared specimens from those patients undergoing immediate resection (Infliximab naïve, n = 20) to those who failed Infliximab therapy (n = 20).

Results

Infliximab naïve and Infliximab failure patients had similar severity of inflammation when asse

SUBMITTER: de Bruyn JR 

PROVIDER: S-EPMC5783363 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature